子宫内膜癌中的KRAS突变:可能的预后与治疗意义
本研究基于7870例子宫内膜癌分子数据库,分析KRAS突变频率及其与其他致癌改变和免疫治疗标志物的关系。KRAS突变见于16%病例,以G12D和G12V最常见,且与MSI-H、TMB-H和PD-L1>1%共现,与Her-2过表达负相关。作者提出KRAS突变代表基因型 distinct 群体,建议开发免疫联合治疗临床试验。
要点
- KRAS突变见于16%的子宫内膜癌,G12D(31%)和G12V(27%)为最常见亚型。
- KRAS突变组MSI-H为34.1%、TMB-H为36.5%,分别高于KRAS野生型的19.8%和16.9%(p<0.05)。
- KRAS突变与Her-2过表达负相关(1.8% vs 13%,p<0.001),作者建议开发免疫联合治疗临床试验。
核心结论
- KRAS突变代表子宫内膜癌中一个基因型独特的群体,与免疫治疗应答的基因组预测标志物(TMB-H、MSI-H)存在重叠,提示可能的生物标志物驱动的免疫联合治疗选择;应开发临床试验评估这些策略。
研究设计与样本
- 查询包含7870例子宫内膜癌的分子数据库,检测致癌突变和免疫治疗标志物。
- 使用Fisher精确检验/卡方检验比较p值,并通过Benjamini-Hochberg方法(q值)校正多重检验,采用Wilcoxon方法进行成对非参数分析。
主要发现
- KRAS突变在子宫内膜癌中检测率为16%,密码子12最常突变,G12D(31%)和G12V(27%)为最常见亚型。
- KRAS突变组MSI-H为34.1%、TMB-H为36.5%,KRAS野生型组分别为19.8%和16.9%(p<0.05)。
- PD-L1>1%在KRAS突变组为8.4%,KRAS野生型组为6.4%(p<0.05)。
- BRCA1/2突变在KRAS突变组和KRAS野生型组频率相似且低(5.9% vs 4.9%,p>0.05)。
- KRAS突变与Her-2过表达负相关(KRAS突变组1.8% vs KRAS野生型组13%,p<0.001)。
临床怎么用
- 作者认为KRAS突变代表基因型独特的子宫内膜癌群体,与免疫治疗应答的基因组预测标志物存在重叠,提示可能的生物标志物驱动的免疫联合治疗选择。
- 作者建议应开发临床试验评估这些策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Patients with recurrent or metastatic endometrial cancer (EC) have poor prognoses with limited therapeutic options following immunotherapy or immunochemotherapy treatments. Inhibitors of KRAS mutations (KRAS-mut) have shown efficacy in early solid tumor studies, but data in EC are lacking. This study describes the frequency of KRAS-mut relative to other oncogenic alterations in EC to identify genomic characteristics of KRAS-mut tumors that could lead to novel therapeutic options. METHODS: A molecular database of 7870 ECs was queried for presence of oncogenic mutations and immunotherapy biomarkers. Comparisons were performed using Fisher-Exact/ChiSquare (p-values) and adjusted for multiple tests by Benjamini-Hochberg (q) and pairwise nonparametric analysis using Wilcoxon Method. RESULTS: KRAS-mut is a relatively frequent genotype in EC, detected in 16% of cases. Codon 12 was most frequently mutated, with G12D (31%) and G12V (27%) the most common subtypes. Biomarkers of immunotherapy response co-occur with KRAS-mut. Microsatellite instability-high and tumor mutational burden-high status were observed in 34.1% and 36.5% in KRAS-mut compared to 19.8% and 16.9% in KRAS-WT, respectively (p < 0.05). PD-L1 >1% was detected in 8.4% vs 6.4% of KRAS-mut vs KRAS-WT (p < 0.05). BRCA1/2 mutations were detected with similar low frequency (5.9% vs 4.9%) among KRAS-mut and KRAS-WT ECs (p > 0.05). KRAS-mut was inversely associated with Her-2 overexpression (1.8% KRAS-mut vs 13% KRAS-WT. (p < 0.001). CONCLUSIONS: KRAS-mut represents a genotypically distinct group of ECs. Overlap exists with genomic predictors (TMB-high, MSI-high) of immunotherapy response, suggesting a possible biomarker-driven combination option with immunotherapy. Clinical trials to evaluate these strategies should be developed.
引用
- Kilowski KA, Dietrich MF, Xiu J, et al. KRAS mutations in endometrial cancers: Possible prognostic and treatment implications. Gynecol Oncol. 2024. PMID: 39500247. doi:10.1016/j.ygyno.2024.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。